Skip to main content
Top
Published in: PharmacoEconomics 1/2007

01-01-2007 | Practical Application

Rates and Probabilities in Economic Modelling

Transformation, Translation and Appropriate Application

Authors: Dr Rachael L. Fleurence, Christopher S. Hollenbeak

Published in: PharmacoEconomics | Issue 1/2007

Login to get access

Abstract

Economic modelling is increasingly being used to evaluate the cost effectiveness of health technologies. One of the requirements for good practice in modelling is appropriate application of rates and probabilities. In spite of previous descriptions of appropriate use of rates and probabilities, confusions persist beyond a simple understanding of their definitions. The objective of this article is to provide a concise guide to understanding the issues surrounding the use of rates and probabilities reported in the literature in economic models, and an understanding of when and how to transform them appropriately. The article begins by defining rates and probabilities and shows the essential difference between the two measures. Appropriate conversions between rates and probabilities are discussed, and simple examples are provided to illustrate the techniques and pitfalls. How the transformed rates and probabilities may be used in economic models is then described and some recommendations are suggested.
Literature
1.
go back to reference Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood) 2004; 23 (1): 124–134CrossRef Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood) 2004; 23 (1): 124–134CrossRef
2.
go back to reference Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461–477PubMedCrossRef Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application. Pharmacoeconomics 2000; 17 (5): 461–477PubMedCrossRef
3.
go back to reference Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6 (3): 217–227PubMedCrossRef Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997; 6 (3): 217–227PubMedCrossRef
4.
go back to reference Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397–409PubMedCrossRef Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13 (4): 397–409PubMedCrossRef
5.
go back to reference Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): 1–172PubMed Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8 (36): 1–172PubMed
6.
go back to reference Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003; 6 (1): 9–17PubMedCrossRef Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices. Modeling studies. Value Health 2003; 6 (1): 9–17PubMedCrossRef
7.
go back to reference Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–58PubMedCrossRef Miller DK, Homan SM. Determining transition probabilities: confusion and suggestions. Med Decis Making 1994; 14: 52–58PubMedCrossRef
8.
go back to reference Hennekens C, Buring J. Epidemiology in medicine. Toronto (ON): Little Brown and Co., 1987 Hennekens C, Buring J. Epidemiology in medicine. Toronto (ON): Little Brown and Co., 1987
9.
go back to reference Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151 (12): 1158–1171PubMedCrossRef Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151 (12): 1158–1171PubMedCrossRef
10.
go back to reference Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine: integrating evidence and values. New York: Cambridge University Press, 2001 Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine: integrating evidence and values. New York: Cambridge University Press, 2001
11.
go back to reference Welton NJ, Ades AE. Estimation of Markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration. Med Decis Making 2005; 25 (6): 633–645PubMedCrossRef Welton NJ, Ades AE. Estimation of Markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration. Med Decis Making 2005; 25 (6): 633–645PubMedCrossRef
Metadata
Title
Rates and Probabilities in Economic Modelling
Transformation, Translation and Appropriate Application
Authors
Dr Rachael L. Fleurence
Christopher S. Hollenbeak
Publication date
01-01-2007
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 1/2007
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200725010-00002

Other articles of this Issue 1/2007

PharmacoEconomics 1/2007 Go to the issue